SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Significant Increase in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) was the target of a large growth in short interest in January. As of January 15th, there was short interest totaling 53,042 shares, a growth of 68.3% from the December 31st total of 31,511 shares. Based on an average daily trading volume, of 137,142 shares, the short-interest ratio is currently 0.4 days. Currently, 0.1% of the shares of the stock are short sold. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 137,142 shares, the short-interest ratio is currently 0.4 days.

SOPHiA GENETICS Stock Performance

Shares of SOPHiA GENETICS stock traded up $0.08 during trading on Friday, hitting $5.25. 217,719 shares of the company’s stock traded hands, compared to its average volume of 290,868. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.80 and a quick ratio of 2.62. SOPHiA GENETICS has a 1 year low of $2.58 and a 1 year high of $5.70. The stock has a market capitalization of $354.80 million, a P/E ratio of -11.41 and a beta of 1.11. The business has a 50-day simple moving average of $4.95 and a 200-day simple moving average of $4.21.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). The company had revenue of $19.46 million for the quarter, compared to analysts’ expectations of $18.13 million. SOPHiA GENETICS had a negative return on equity of 37.75% and a negative net margin of 41.13%. As a group, analysts forecast that SOPHiA GENETICS will post -0.96 EPS for the current year.

Hedge Funds Weigh In On SOPHiA GENETICS

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after acquiring an additional 5,432,871 shares during the period. Rathbones Group PLC bought a new stake in shares of SOPHiA GENETICS in the 2nd quarter worth approximately $504,000. Ensign Peak Advisors Inc purchased a new position in SOPHiA GENETICS during the second quarter valued at $775,000. Archon Capital Management LLC purchased a new stake in SOPHiA GENETICS during the 2nd quarter valued at $997,000. Finally, Federated Hermes Inc. grew its holdings in SOPHiA GENETICS by 16.4% during the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock valued at $682,000 after buying an additional 31,000 shares in the last quarter. Institutional investors own 31.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SOPH. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. BTIG Research upped their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Wall Street Zen upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Saturday, November 1st. Finally, Guggenheim boosted their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.